Skip to content

Financial Information

This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQKPTI
Beta(0.19)
Shares Outstanding114.5M
Average Volume (10 days)1.9M
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.31)
Sales (TTM)$1.37
Book Value (MRQ)($0.88)
Cash Flow (TTM)($0.88)
Cash (MRQ)$1.82

Analyst Views

Current Mean RecommendationStrong Buy
Strong Buy5
 
Buy1
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Poulton Stuart
EVP, Chief Development Officer
(5,748)
Sell
Feb 15, 2024
Poulton Stuart
EVP, Chief Development Officer
(99)
Sell
Feb 15, 2024
Paulson Richard
President and CEO
(4,012)
Sell
Feb 6, 2024
Paulson Richard
Ceo/President
(4,012)
Sell
Feb 6, 2024
Michael P. Mason
EVP, CFO, Treasurer
(4,205)
Sell
Feb 6, 2024

Recent SEC Filings

Insider Buy/Sell
Feb 20, 2024
Company Events
Feb 20, 2024
Amended >= 5% Acquisition
Feb 14, 2024
Amended >= 5% Acquisition
Feb 14, 2024
>= 5% Acquisition
Feb 13, 2024
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.